Related Experiment Videos
Tissue plasminogen activator in the treatment of vitreoretinal diseases
M Kamei1, M Estafanous, H Lewis
1Department of Ophthalmology, Osaka University Medical School, Suita, Japan. mkamei@ophthal.med.osaka-u.ac.jp
Abstract:
Tissue plasminogen activator (tPA) is a thrombolytic agent that activates plasminogen into plasmin almost exclusively in the presence of fibrin. Intraocular injection of tPA has been proposed for the treatment of vitreoretinal diseases, such as vitreous hemorrhage, postvitrectomy fibrin formation, submacular hemorrhage, retinal vascular occlusive disorders, suprachoroidal hemorrhage and endophthalmitis. Currently, intraocular tPA is only used in the treatment of postvitrectomy fibrin formation and submacular hemorrhage. For other indications, tPA has not been shown to be safe or effective. This article reviews the use of tPA in the treatment of vitreoretinal disorders.